CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2 enrolled
Drug / intervention
Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04452292
NCT04452292N/ACompleted
CompareCT.gov

A Pilot Feasibility Study of Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma

Charles Kunos·interventional·Posted Jun 30, 2020·Updated May 17, 2023

In Brief

A clinical study evaluating Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinoma and Treatment for Small Cell Lung Cancer for Large-Cell Neuroendocrine Carcinoma. Completed, enrolled 2 participants across 1 site.

Detailed Summary

PRECISION-NEC is a single-center, open-label, pilot feasibility study of molecularly defined subtypes of metastatic high-grade neuroendocrine carcinoma (HG-NEC). The hypothesis is that HG-NEC (excluding small cell carcinoma) can be segregated based on mutational analysis and that next generation sequencing (NGS)-based assignment of therapy is feasible and will potentially improve the outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLarge-Cell Neuroendocrine Carcinoma
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJun 30, 2020
Enrollment StartSep 14, 2021
Primary CompletionMay 4, 2022
Study CompletionMar 14, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.0 years ago

Interventions

Treatment Specific for Non-Small Cell Carcinoma/Adenocarcinomaother

Treatment assigned to targetable mutation. Or, for tumors that are by and large without any targetable mutation follow Large-Cell Neuroendocrine Carcinoma (NCCN) guideline-directed best front-line treatment for specific non-small cell carcinoma/adenocarcinoma.

Treatment for Small Cell Lung Cancerother

Treatment assigned to a targetable mutation or the current standard-of-care regimen for the treatment of small cell lung cancer.